Earnings Feed
Start Free
Home/Filings/4/0000899243-17-023140
4//SEC Filing

New Leaf Biopharma Opportunities I, L.P. 4

Accession 0000899243-17-023140

CIK 0001654151other
View on SEC.govCompany Profile

Filed

Oct 1, 8:00 PM ET

Accepted

Oct 2, 4:42 PM ET

Size

35.6 KB

Accession

0000899243-17-023140

Insider Transaction Report

Form 4
Period: 2017-10-02
Deciphera Pharmaceuticals, Inc.DCPH
New Leaf Venture Management III, L.L.C.
10% Owner
Transactions
  • Conversion

    Common Stock

    2017-10-02+1,118,722→ 1,398,425 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2017-10-02+1,118,722→ 1,957,832 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2017-10-02+279,703→ 279,703 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2017-10-02$17.00/sh+375,000$6,375,000→ 2,146,308 total(indirect: See Footnote)
  • Conversion

    Series B-1 Preferred Stock

    2017-10-02−148,515→ 0 total(indirect: See Footnote)
    → Common Stock (839,110 underlying)
  • Conversion

    Series B-1 Preferred Stock

    2017-10-02−49,505→ 0 total(indirect: See Footnote)
    → Common Stock (279,703 underlying)
  • Conversion

    Series B-2 Preferred Stock

    2017-10-02−198,004→ 0 total(indirect: See Footnote)
    → Common Stock (1,118,722 underlying)
  • Conversion

    Series B-2 Preferred Stock

    2017-10-02−198,004→ 0 total(indirect: See Footnote)
    → Common Stock (1,118,722 underlying)
  • Conversion

    Common Stock

    2017-10-02+839,110→ 839,110 total(indirect: See Footnote)
  • Conversion

    Series C Preferred Stock

    2017-10-02−65,997→ 0 total(indirect: See Footnote)
    → Common Stock (372,883 underlying)
  • Conversion

    Common Stock

    2017-10-02+372,883→ 1,771,308 total(indirect: See Footnote)
New Leaf Biopharma Opportunities I, L.P.
10% Owner
Transactions
  • Conversion

    Series B-1 Preferred Stock

    2017-10-02−49,505→ 0 total(indirect: See Footnote)
    → Common Stock (279,703 underlying)
  • Conversion

    Common Stock

    2017-10-02+1,118,722→ 1,957,832 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2017-10-02$17.00/sh+375,000$6,375,000→ 2,146,308 total(indirect: See Footnote)
  • Conversion

    Series B-1 Preferred Stock

    2017-10-02−148,515→ 0 total(indirect: See Footnote)
    → Common Stock (839,110 underlying)
  • Conversion

    Series C Preferred Stock

    2017-10-02−65,997→ 0 total(indirect: See Footnote)
    → Common Stock (372,883 underlying)
  • Conversion

    Common Stock

    2017-10-02+1,118,722→ 1,398,425 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2017-10-02+839,110→ 839,110 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2017-10-02+279,703→ 279,703 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2017-10-02+372,883→ 1,771,308 total(indirect: See Footnote)
  • Conversion

    Series B-2 Preferred Stock

    2017-10-02−198,004→ 0 total(indirect: See Footnote)
    → Common Stock (1,118,722 underlying)
  • Conversion

    Series B-2 Preferred Stock

    2017-10-02−198,004→ 0 total(indirect: See Footnote)
    → Common Stock (1,118,722 underlying)
New Leaf Venture Associates III, L.P.
10% Owner
Transactions
  • Conversion

    Common Stock

    2017-10-02+1,118,722→ 1,398,425 total(indirect: See Footnote)
  • Conversion

    Series B-1 Preferred Stock

    2017-10-02−148,515→ 0 total(indirect: See Footnote)
    → Common Stock (839,110 underlying)
  • Conversion

    Series C Preferred Stock

    2017-10-02−65,997→ 0 total(indirect: See Footnote)
    → Common Stock (372,883 underlying)
  • Conversion

    Common Stock

    2017-10-02+1,118,722→ 1,957,832 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2017-10-02+279,703→ 279,703 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2017-10-02+372,883→ 1,771,308 total(indirect: See Footnote)
  • Conversion

    Series B-2 Preferred Stock

    2017-10-02−198,004→ 0 total(indirect: See Footnote)
    → Common Stock (1,118,722 underlying)
  • Conversion

    Series B-2 Preferred Stock

    2017-10-02−198,004→ 0 total(indirect: See Footnote)
    → Common Stock (1,118,722 underlying)
  • Conversion

    Common Stock

    2017-10-02+839,110→ 839,110 total(indirect: See Footnote)
  • Conversion

    Series B-1 Preferred Stock

    2017-10-02−49,505→ 0 total(indirect: See Footnote)
    → Common Stock (279,703 underlying)
  • Purchase

    Common Stock

    2017-10-02$17.00/sh+375,000$6,375,000→ 2,146,308 total(indirect: See Footnote)
New Leaf BPO Associates I, L.P.
10% Owner
Transactions
  • Conversion

    Common Stock

    2017-10-02+1,118,722→ 1,957,832 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2017-10-02+279,703→ 279,703 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2017-10-02+1,118,722→ 1,398,425 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2017-10-02$17.00/sh+375,000$6,375,000→ 2,146,308 total(indirect: See Footnote)
  • Conversion

    Series B-2 Preferred Stock

    2017-10-02−198,004→ 0 total(indirect: See Footnote)
    → Common Stock (1,118,722 underlying)
  • Conversion

    Series B-2 Preferred Stock

    2017-10-02−198,004→ 0 total(indirect: See Footnote)
    → Common Stock (1,118,722 underlying)
  • Conversion

    Series C Preferred Stock

    2017-10-02−65,997→ 0 total(indirect: See Footnote)
    → Common Stock (372,883 underlying)
  • Conversion

    Common Stock

    2017-10-02+839,110→ 839,110 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2017-10-02+372,883→ 1,771,308 total(indirect: See Footnote)
  • Conversion

    Series B-1 Preferred Stock

    2017-10-02−148,515→ 0 total(indirect: See Footnote)
    → Common Stock (839,110 underlying)
  • Conversion

    Series B-1 Preferred Stock

    2017-10-02−49,505→ 0 total(indirect: See Footnote)
    → Common Stock (279,703 underlying)
New Leaf Ventures III, L.P.
10% Owner
Transactions
  • Conversion

    Series B-2 Preferred Stock

    2017-10-02−198,004→ 0 total(indirect: See Footnote)
    → Common Stock (1,118,722 underlying)
  • Conversion

    Series B-2 Preferred Stock

    2017-10-02−198,004→ 0 total(indirect: See Footnote)
    → Common Stock (1,118,722 underlying)
  • Conversion

    Common Stock

    2017-10-02+839,110→ 839,110 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2017-10-02+1,118,722→ 1,957,832 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2017-10-02+279,703→ 279,703 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2017-10-02+1,118,722→ 1,398,425 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2017-10-02+372,883→ 1,771,308 total(indirect: See Footnote)
  • Conversion

    Series B-1 Preferred Stock

    2017-10-02−148,515→ 0 total(indirect: See Footnote)
    → Common Stock (839,110 underlying)
  • Conversion

    Series B-1 Preferred Stock

    2017-10-02−49,505→ 0 total(indirect: See Footnote)
    → Common Stock (279,703 underlying)
  • Purchase

    Common Stock

    2017-10-02$17.00/sh+375,000$6,375,000→ 2,146,308 total(indirect: See Footnote)
  • Conversion

    Series C Preferred Stock

    2017-10-02−65,997→ 0 total(indirect: See Footnote)
    → Common Stock (372,883 underlying)
Footnotes (5)
  • [F1]Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer.
  • [F2]The reportable securities are owned directly by New Leaf Ventures III, L.P. ("NLV III"). New Leaf Venture Associates III, L.P. ("NLV Associates III") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. ("NLV Management III") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. ("NLVP") is the investment adviser of NLV III. Each of NLV Associates III and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLV Associates III or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
  • [F3](Continuation from footnote 2) Each of Liam Ratcliffe, a member of the Issuer's board of directors, Jeani Delagardelle, Ronald M. Hunt and Vijay K. Lathi (each, a "Member" and collectively, the "Members") is a member of NLV Management III and may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
  • [F4]The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. ("Biopharma I"). New Leaf BPO Associates I, L.P. ("NLBA I") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
  • [F5](Continuation from footnote 4) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Documents

1 file

Issuer

Deciphera Pharmaceuticals, Inc.

CIK 0001654151

→
Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001625696

Filing Metadata

Form type
4
Filed
Oct 1, 8:00 PM ET
Accepted
Oct 2, 4:42 PM ET
Size
35.6 KB
View on SEC.gov